1FW

NOV 0 4 2005 S

Docket No. CRD5063USANP

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert Falotico, et al.

Serial No.: 10/761,032

Art Unit: 3761

Filed

: January 20, 2004

Examiner: Thurman Page

For

: LOCAL VASCULAR DELIVERY OF MYCOPHENOLIC ACID IN COMBINATION WITH RAPAMYCIN TO PREVENT RESTENOSIS

FOLLOWING VASCULAR INJURY

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

November 1, 2005
(Date of Deposit)

Carl J. Evens
(Name of applicant, assignee, or Registered Representative)

/Carl J. Evens/
(Signature)

November 1, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

(Date of Signature)

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

نسة

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information \boxtimes Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is

accompanied by one of:

	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
Disclosure Steither a Final under §1.31. Applicant(s) Information I Accordance with \$180.00 as see	accordance with §1.97(d), this Information catement is being filed after the mailing date of al Action under §1.113 or a Notice of Allowance but before the payment of the Issue Fee. hereby petition(s) for consideration of this Disclosure Statement. Included are: Statement in §1.97(e) as set forth below and the fee of et forth in §1.17(p).
attached Form	n PTO-1449 are enclosed herewith.
_	pies of references listed on the attached Form PTC losed herewith EXCEPT THAT:
	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
	pies of only foreign patent documents and non- ature are enclosed in accordance with 37 CFR 1.98
(a)(2).	teare are enerosed in accordance with 37 cfk 1.50
\~/ \~/ ·	

There are no listed English language.	references which are not in the
The relevance of the not in the English language is	ose listed references which are s as follows:
	of search report(s) from ion(s), which are listed on the P 609 D.
_	llowing non-published pending be deemed relevant, which are sion Under MPEP 609 D.
	ency or credit any overpayment to RD5063USANP/CJE. This form is
<u>-</u>	Respectfully submitted,
	/Carl J. Evens/
	Carl J. Evens Reg. No. 33,874 Attorney for Applicants
Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003	

(732) 524-2518 DATED: November 1, 2005



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control numbe

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 4

a collection of information unless it displays a valid ONB control number.			
Application Number	10/761,032		
Filing Date	January 20, 2004		
First Named Inventor	Robert Falotico		
Group Art Unit	3761		
Examiner Name	T. Page		
Attorney Docket Number	CRD5063USANP		

		Silectio	ı - ₹	U.S. PATENT DOCUMENTS		***************************************
U.S. Patent Document						
Examiner Initials	Cite No.1		nd Code ² f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
_		3,929,992		Sehgal et al.	12/30/1975	
		3,959,078		Guire et al.	05/25/1976	
		4,350,160		Kolesov et al.	09/21/1982	
		4,366,819		Kaster	01/4/1983	
		4,624,257		Berggren et al.	11/25/1986	
		4,722,906		Guire et al.	02/02/1988	
		4,733,665		Palmaz	03/29/1988	
		4,739,762		Palmaz	04/26/1988	
-		4,776,337		Palmaz	10/11/1988	
		4,917,090		Berggren et al.	04/17/1990	
		4,917,091		Berggren et al.	04/17/1990	
		5,229,172		Cahalan et al.	07/20/1993	
-		5,234,447		Kaster et al.	08/10/1993	
		5,308,641		Cahalan et al.	05/03/1994	
		5,350,800		Cahalan et al.	09/27/1994	
		5,415,938		Cahalan et al.	05/16/1995	
		5,837,313		Ding et al.	11/17/1998	
		6,099,562		Ding et al.	08/08/2000	
		6,120,536		Ding et al.	09/19/2000	
		6,153,252		Hossainy et al.	11/28/2000	
		6,425,898	B1	Wilson et al.	07/30/2002	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 4

a concessor of information unless it displays a valid Civil control number.				
Application Number	10/761,032			
Filing Date	January 20, 2004			
First Named Inventor	Robert Falotico			
Group Art Unit	3761			
Examiner Name	T. Page			
Attorney Docket Number	CRD5063USANP			
	i			

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document		nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number⁴ Ki	ndCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		PCT	98/33443					

Examiner	 Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 4

d concessor of information unless it displaye a valie of the contest frames.				
Application Number	10/761,032			
Filing Date	January 20, 2004			
First Named Inventor	Robert Falotico			
Group Art Unit	3761			
Examiner Name	T. Page			
Attorney Docket Number	CRD5063USANP			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
•		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T ²
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	1-
initials	NO.	publisher, city and/or country where published CLOWES, A.W and KARNOVSKY M., Nature 265:25-26, 1977	
		GUYTON, J.R. ET AL., Circ. Res., 46:625-634, 1980	
		CLOWES, A.W. AND CLOWES, M.M., Lab. Invest. <u>52</u> :611-616, 1985	
		CLOWES, A.W. AND CLOWES, M.M., Circ. Res. <u>58</u> :839-845, 1986	
•		MAJESKY ET AL., Circ. Res. 61:296-300, 1987	
		SNOW ET AL., Am. J. Pathol. 137:313-330, 1990	
		OKADA T. ET AL., Neurosurgery 25: 92-98, 1989	
		CURRIER, J.W. ET AL., Circ. 80:11-66, 1989	
		SOLLOT, S.J. ET AL., J. Clin. Invest. 95: 1869-1876, 1995	
		POWELL, J. S. ET AL., Science, <u>245</u> : 186-188, 1989	
		LUNDERGAN, C. F. ET AL., Am J. Cardio. <u>17</u> (Suppl. B): 132B-136B, 1991	
		JONASSON, I. ET AL., Proc. Natl., Acad. Sci., 85: 2303, 1988	
		FERNS, G.A.A., ET AL., Science <u>253</u> : 1129-1132, 1991	
		NEMECEK, G.M. ET AL., J. Pharmacol Exp.Thera. <u>248</u> : 1167-1174, 1989	
		LIU, M.W. ET AL., Circ. <u>81</u> : 1089-1093, 1990	
		FUKUYAMA, J. ET AL., Eur. J. Pharmacol. <u>318</u> : 327-332, 1996	
		HANSSON, G.K. AND HOLM, J. Circ. <u>84</u> : 1266-1272, 1991	·
		MARX, S.O. ET AL., Circ. Res. <u>76</u> : 412-417, 1995	
		COLBURN, M.D. ET AL., J. VASC. SURG. <u>15</u> : 510-518, 1992	
	<u> </u>	BERK, B.C. ET AL., J. Am. Coll. Cardiol. <u>17</u> : 111B-117B, 1991	
		WEINBERGER, J. ET AL., Int. J. Rad. Onc. Biol. Phys. <u>36</u> : 767-775, 1996	
		FARB, A. ET AL., Circ. Res. <u>80</u> :542-550, 1997	
		SIMONS, M. ET AL., Nature <u>359</u> : 67-70, 1992	
		CHANG, M.W. ET AL., J. Clin. Invest. <u>96</u> : 2260-2268, 1995	
		MODERN FLUOROPOLYMERS, (J Shires ed.), John Wiley & Sons, New York,	
		1997, pp. 77-87	
		AJROLDI, ET AL., Fluoroelastomers-dependence of relaxation Phenomena on	
		Compositions, Polymer 30, 2180, 1989	
		HANSON & HARKER, Proc. Natl. Acad. Sci. USA 85:3184-3188, 1988	<u> </u>

_			
	Examiner	Date	
- [:	Signature	Considere	d I

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE o a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 4 of 4

a collection of information unless it displays a valid Civib control fidinger.			
Application Number	10/761,032		
Filing Date	January 20, 2004		
First Named Inventor	Robert Falotico		
Group Art Unit	3761		
Examiner Name	T. Page		
Attorney Docket Number	CRD5063USANP		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	-
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Initials*	No.' publisher, city and/or country where published		
		WOO ET AL., J. Med Chem, <u>45</u> :2877-2885, 2002	
	Ì	DEROANNE ET AL., Oncogene 21(3): 427-436, 2002	
186.4			
		-	
		1	
			•
		A MANAGEMENT CONTROL OF THE CONTROL	
·	<u> </u>		
	 -		
	ļ		·
	1		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.